Hematology News

ORLANDO — Patients with catastrophic antiphospholipid syndrome appeared to have high rates of mutations in complement regulatory genes that could lead to uncontrolled complement activation and a more severe phenotype, according to study results presented during the plenary session of ASH Annual Meeting and Exposition.

ORLANDO — In this video at the ASH Annual Meeting and Exposition, Jeffrey I. Weitz, MD, FRCPC, professor of medicine and executive director of the Thrombosis and Atherosclerosis Research Institute at McMaster University in Hamilton, Canada, discusses his lecture on the role of factor XI inhibitors in anticoagulant therapy.

ORLANDO — A new microvascular-on-a-chip assay has allowed researchers to grow blood clots and track inflammatory thrombi with the goal of better targeting antithrombotic and anticoagulant therapies, according to results of a study presented at ASH Annual Meeting and Exposition.

ORLANDO — Body weight-adjusted regimens of rivaroxaban appeared to be safe and effective for children with venous thromboembolism, according to results of a dose-exposure-response evaluation of the phase 3 EINSTEIN-Jr. study presented at ASH Annual Meeting and Exposition.

ORLANDO — Interim results of an international survey presented at the ASH Annual Meeting and Exposition indicate that complications of sickle cell disease, including vaso-occlusive crisis events as well as poor functioning and quality of life, may be underestimated.

ORLANDO — The addition of aspirin to direct oral anticoagulant therapy for venous thromboembolism or nonvalvular atrial fibrillation appeared associated with increased rates of bleeding events compared with use of the anticoagulants alone, according to results of a registry-based cohort study presented at ASH Annual Meeting at Exposition.

The FDA warned Liveyon Labs Inc. and Liveyon LLC, as well as their top executives, for processing and distributing unapproved products derived from umbilical cord blood, according to an agency news release.

During a recent webinar, ASH President Roy L. Silverstein, MD, highlighted three “potentially practice-changing” abstracts on venous thromboembolism that will be presented at the upcoming meeting in Orlando, Fla.

The combination of a D-dimer level below 1,000 ng/mL and low clinical pretest probability correctly identified a group of patients at low risk for pulmonary embolism during follow-up, according to results of a prospective study published in The New England Journal of Medicine.

The FDA granted accelerated approval to voxelotor for the treatment of sickle cell disease.